1. Home
  2. CINGW vs FRES Comparison

CINGW vs FRES Comparison

Compare CINGW & FRES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • FRES
  • Stock Information
  • Founded
  • CINGW N/A
  • FRES 2010
  • Country
  • CINGW United States
  • FRES United States
  • Employees
  • CINGW 13
  • FRES N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • FRES Medical Specialities
  • Sector
  • CINGW Health Care
  • FRES Health Care
  • Exchange
  • CINGW Nasdaq
  • FRES Nasdaq
  • Market Cap
  • CINGW N/A
  • FRES N/A
  • IPO Year
  • CINGW 2021
  • FRES 2020
  • Fundamental
  • Price
  • CINGW $0.07
  • FRES $1.40
  • Analyst Decision
  • CINGW
  • FRES
  • Analyst Count
  • CINGW 0
  • FRES 0
  • Target Price
  • CINGW N/A
  • FRES N/A
  • AVG Volume (30 Days)
  • CINGW N/A
  • FRES 99.8K
  • Earning Date
  • CINGW N/A
  • FRES 10-15-2024
  • Dividend Yield
  • CINGW N/A
  • FRES N/A
  • EPS Growth
  • CINGW N/A
  • FRES N/A
  • EPS
  • CINGW N/A
  • FRES N/A
  • Revenue
  • CINGW N/A
  • FRES $2,341,326.00
  • Revenue This Year
  • CINGW N/A
  • FRES N/A
  • Revenue Next Year
  • CINGW N/A
  • FRES N/A
  • P/E Ratio
  • CINGW N/A
  • FRES N/A
  • Revenue Growth
  • CINGW N/A
  • FRES 94.50
  • 52 Week Low
  • CINGW N/A
  • FRES $1.11
  • 52 Week High
  • CINGW N/A
  • FRES $18.00
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • FRES 41.51
  • Support Level
  • CINGW N/A
  • FRES $1.11
  • Resistance Level
  • CINGW N/A
  • FRES $1.72
  • Average True Range (ATR)
  • CINGW 0.00
  • FRES 0.29
  • MACD
  • CINGW 0.00
  • FRES 0.00
  • Stochastic Oscillator
  • CINGW 0.00
  • FRES 20.95

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: